Episode Details

When the diagnostic test PrecivityAD hit the market in 2020, it democratized early detection of Alzheimer’s disease. The blood test, developed by C2N Diagnostics, is more accessible than brain imaging and spinal fluid tests, which can be expensive and invasive. WashU Medicine professor and C2N Diagnostics co-founder Dr. David Holtzman talks about his team’s innovation and how their work has contributed to our understanding of the disorder and how to treat it. He also shares how the commercialization process afforded to universities through the Bayh-Dole Act of 1980 has brought innovative discoveries like PrecivityAD to the general public. Holtzman and his colleague, Dr. Randall Bateman, will receive the American Innovator Award from the Bayh-Dole Coalition in Washington, D.C. next week.